This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Peptimmune, Inc.

Drug Names(s): GT389-255

Description: GT 389-255 is a novel conjugate of a proprietary pancreatic lipase inhibitor and a fat binding hydrogel polymer for the treatment of obesity. It acts within the gastro-intestinal tract to prevent fat digestion and is expected to inhibit more than 30% of fat absorption. The novel conjugate is expected to have fewer side-effects than currently marketed therapies. The currently marketed pancreatic lipase inhibitor Orlistat, is associated with oily incontinence, caused by mal-absorbed triglycerides. GT 389-255 is expected to have minimal systemic exposure. Less than 1% of the lipase inhibitor is absorbed and the fat binding polymer is not absorbed.

Deal Structure: In May 2004, Genzyme and Peptimmune announced that Genzyme has granted an exclusive worldwide license to Peptimmune to develop and market a Genzyme investigational drug candidate for the treatment of obesity and other metabolic disease indications. Under the agreement, Genzyme grants Peptimmune exclusive rights to develop, manufacture and commercialize GT389-255, in exchange for royalties, in addition to shared milestones and payments if the program is partnered further. Financial details were not disclosed.

In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.

Partners: Sanofi

GT389-255 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug